2,906
Views
4
CrossRef citations to date
0
Altmetric
Gastroenterology & Hepatology

Adiponectin–leptin ratio for the early detection of lean non-alcoholic fatty liver disease independent of insulin resistance

, , , , , , & ORCID Icon show all
Pages 634-642 | Received 27 Oct 2022, Accepted 06 Feb 2023, Published online: 15 Feb 2023

Figures & data

Table 1. Baseline characteristics among the lean controls, lean NAFLD, simple overweight/obesity and overweight/obesity NAFLD groups.

Table 2. Relation between the serum adiponectin-leptin ratio and metabolic factors in multivariate linear regression models after adjusting for age and sex.

Table 3. Odds ratios of having NAFLD in relation to the serum tertile of adiponectin-leptin (AL × 103) ratio using multiple logistic regression analyses.

Table 4. Odds ratios of having NAFLD in relation to serum tertile of adiponectin leptin level using multiple logistic regression analyses, stratification by BMI.

Figure 1. Receiver operating characteristic (ROC) for the diagnosis of NAFLD. Except adiponectin-leptin ratio, BMI, triglyceride and AST/ALT ratio were selected. (A) All subjects, AUROC was 0.85 (95% CI: 0.82–0.88), (B) female subjects, AUROC was 0.83 (0.78–0.87), and (C) male subjects, AUROC was 0.86 (081–0.91). All p < .001.

Figure 1. Receiver operating characteristic (ROC) for the diagnosis of NAFLD. Except adiponectin-leptin ratio, BMI, triglyceride and AST/ALT ratio were selected. (A) All subjects, AUROC was 0.85 (95% CI: 0.82–0.88), (B) female subjects, AUROC was 0.83 (0.78–0.87), and (C) male subjects, AUROC was 0.86 (081–0.91). All p < .001.

Data availability statement

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.